DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Atgam (Equine Thymocyte Immune Globulin) - Published Studies


Atgam Related Published Studies

Well-designed clinical trials related to Atgam (Equine Thymocyte Immune Globulin)

A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. [2008.10.15]

Well-designed clinical trials possibly related to Atgam (Equine Thymocyte Immune Globulin)

A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation. [2014]

Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. [2011.08.04]

Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study. [2011.07]

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. [2011.06.09]

Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. [2011.06]

Alemtuzumab induction in renal transplantation. [2011.05.19]

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. [2011.04.28]

Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. [2011.03]

Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. [2011.03]

Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. [2011.01.20]

The effects of early rapid corticosteroid reduction on cell-mediated immunity in kidney transplant recipients. [2011.01.15]

Antithymocyte globulin induction therapy in heart transplantation: prospective randomized study of high vs standard dosage. [2010.11]

ATG-Fresenius Treatment and Low-Dose Tacrolimus: Results of a Randomized Controlled Trial in Liver Transplantation. [2010.10]

Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. [2010.09]

Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. [2010.07.27]

Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. [2010.06.27]

Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction. [2010.03.01]

Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. [2010.02]

Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. [2010]

A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. [2009.09.27]

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. [2009.09]

Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. [2009.06]

Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. [2009.03]

20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. [2008.12.27]

Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. [2008.05.27]

Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. [2008.05]

Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection. [2008.01]

ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis. [2008]

ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial. [2008]

Safety and efficacy of high dose ATG bolus administration on rewascularization in kidney graft patients - long term results. [2008]

Long-term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation. [2008]

Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia. [2007.12]

Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. [2007.09.15]

Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. [2007.07.15]

Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. [2007.07]

Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin. [2007.07]

Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. [2007.05.15]

A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. [2007.05]

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. [2007.04.15]

Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids. [2007.03.27]

A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. [2007.03.15]

Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. [2007.03]

Other possibly related research studies

Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine. [2010.07]

Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. [2010.08.15]

Treatment of hepatitis C in renal transplantation candidates: a single-center experience. [2010.08.27]

The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins. [2010.08]

Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. [2010.06]

Adenovirus infections in pediatric small bowel transplant recipients. [2010.07.27]

[Female case of successful engraftment after PBSCT from her HLA-haploidentical son for severe aplastic anemia during maintenance peritoneal dialysis] [2010.04]

Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring. [2010]

Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. [2010.05.27]

End-stage renal disease after orthotopic heart transplantation: a single-institute experience. [2010.04]

Unplanned readmission within 1 year after heart transplantation in Taiwan. [2010.04]

Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience. [2010.04]

Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience. [2010.04]

Effect of pretransplantation hemoglobin blood concentration on renal allograft survival and function. [2010.04]

Whole-animal senescent cytotoxic T cell removal using antibodies linked to magnetic nanoparticles. [2010.04]

Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. [2010.09]

Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success. [2010.04]

Induction therapy: why, when, and which agent? [2010.05]

Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. [2010.06]

Renal allograft failure predictors after PAK transplantation: results from the New England Collaborative Association of Pancreas Programs. [2010.06.15]

Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. [2010.05]

Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia--a single-center analysis of 100 patients. [2010.03]

Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. [2010.02.27]

Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. [2010.01]

Outcome of exfoliative rejection after isolated intestinal transplantation in an adult: case report. [2010.01]

Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. [2010.04]

Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. [2010.02.15]

Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. [2010.02.15]

Interleukin-15 receptor blockade in non-human primate kidney transplantation. [2010.04.27]

Thymoglobulin--new approaches to optimal outcomes. [2009.07]

Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab. [2010.06]

[Monoclonal antibodies in organ transplantation] [2009.12]

[From the ancient serotherapy to naked antibodies: a century of successful targeted therapies] [2009.12]

Postexposure prophylaxis of H1N1 with oseltamivir in a newly transplanted kidney recipient receiving intense immunosuppressive therapy. [2009.12]

Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. [2009.12]

Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. [2010.01]

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. [2010.04]

Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. [2009.10.15]

Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. [2009.10.15]

Dissociation between peripheral blood chimerism and tolerance to hindlimb composite tissue transplants: preferential localization of chimerism in donor bone. [2009.09.27]

Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. [2009.11]

Misleading de novo detection of serum anti-HLA-A3 antibodies in kidney recipients having received ATG before transplantation. [2010.02]

Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. [2010.02.01]

Comparison of cyclosporine and tacrolimus in combination with rabbit antithymocyte immunoglobulins as induction therapy in cardiac transplantation. [2009.10]

Long-term kinetics of a T-lymphocytes subset in kidney transplant recipients: relationship with posttransplant malignancies. [2009.10]

Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience. [2009.10]

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. [2010.02]

Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia. [2009.11]

Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. [2009.11]

Association of human leukocyte antigen class II alleles with response to immunosuppressive therapy in Korean aplastic anemia patients. [2010.01]

Iron chelation therapy for patients with myelodysplastic syndrome. [2009]

Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. [2009.11]

Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. [2009.10]

Anti-thymocyte globulin as an adjunct to treatment of fulminant lymphocytic myocarditis. [2009.11]

Calculated withdrawal of low-dose immunosuppression based on a detailed immunological monitoring after kidney transplantation between monocygotic twins. [2009.12]

Cytomegalovirus-induced adrenal insufficiency in a renal transplant recipient. [2009.09]

The role of different risk factors in clinical presentation of hemorrhagic cystitis in hematopoietic stem cell transplant recipients. [2009.09]

Could prophylactic monoclonal antibody improve kidney graft survival? [2009.09]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017